Hit enter to search or ESC to close
Sigrid Therapeutics
  • About Us
    • Our Story
    • The Team
    • Board of Directors
    • Advisory Board
  • R&D
    • SiPore®
    • Clinical Trials
    • Prediabetes
    • Pipeline
    • Posters & Publications
  • Resources
    • Logo
  • News
    • Media
    • Blog (English)
    • Blogs (Swedish)
    • Photos
  • Contact Us
  • Consumer Prelaunch Program
Sigrid Therapeutics
News

Sigrid Therapeutics tar in ytterligare 10,6 miljoner kronor i övertecknad företrädesemission för att påskynda kommersialiseringen av SiPore®

Sigrid Therapeutics tar in ytterligare 10,6 miljoner kronor i övertecknad företrädesemission för att påskynda kommersialiseringen…
Sana
SanaJanuary 17, 2023
News

Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization

Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization Swedish…
Sana
SanaJanuary 17, 2023
News

Sigrid Therapeutics utser Mattias Ankerberg, en internationell ledarprofil från konsumentvarubranschen till ordförande

Sigrid Therapeutics utser Mattias Ankerberg, en internationell ledarprofil från konsumentvarubranschen till ordförande Företaget siktar mot…
Sana
SanaOctober 24, 2022
News

Sigrid Therapeutics appoints internationally established consumer industry executive Mattias Ankarberg as Chairman

Sigrid Therapeutics appoints internationally established consumer industry executive Mattias Ankarberg as Chairman Company aims to…
Sana
SanaOctober 24, 2022
News

Sigrid Therapeutics siktar mot konsumentmarknaden – erbjuder gratis testning av kliniskt bevisad produkt mot fetma och diabetes inför lansering

Sana
SanaJune 1, 2022
News

Nyutvecklad behandling mot fetma och diabetes

Sana
SanaJune 1, 2022
News

Scientific study suggests that mesoporous silica particles (MSPs) interact with the lipid digestion and absorption pathways to reduce calorific uptake

Stockholm, March 21st, 2022: Sigrid Therapeutics today announced the publication of a multifaceted, scientific study…
Sana
SanaMarch 21, 2022
News

Sigrid Therapeutics granted European patent covering the use of porous SiPore® silica particles as pharmaceutical or dietary active ingredients

Stockholm, Sweden March 7, 2022. Sigrid Therapeutics, a Swedish healthtech company specializing in the prevention…
Sana
SanaMarch 7, 2022
News

Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named Sweden’s Female Founder of the Year 2021

Sana
SanaNovember 30, 2021
News

Sigrid Therapeutics tar in 72 Mkr i nytt kapital

Kapitalet kommer från amerikanska, irländska och svenska investerare för att finansiera klinisk studie och internationell…
Sana
SanaNovember 10, 2021
Next Entries »

© 2023 Sigrid Therapeutics.

    • About Us
      • Our Story
      • The Team
      • Board of Directors
      • Advisory Board
    • R&D
      • SiPore®
      • Clinical Trials
      • Prediabetes
      • Pipeline
      • Posters & Publications
    • Resources
      • Logo
    • News
      • Media
      • Blog (English)
      • Blogs (Swedish)
      • Photos
    • Contact Us
    • Consumer Prelaunch Program